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Background: The value of concurrent chemoradiotherapy (CRT) for treatment of locally
advanced non-small cell lung cancer (NSCLC) in elderly and multimorbid patients is
generally disputed due to the assumed lack of toxicity compensation or the limited
prognosis of the accompanying morbidity.
Aim: We investigated correlation between impaired organ function, age, tumor-
associated symptoms, social factors and acute toxicity as well as survival following CRT.
Patients and methods: Retrospective data collection and analysis were performed on the
variables age, functional parameters: FEV1, VC, DLCO, LVEF, creatinine clearance, age,
several categories of comorbidities, WHO performance status, alcohol and nicotine habits,
toxicity according CTC-criteria and survival of all patients (n ¼ 66) with inoperable NSCLC
suffering substantial comorbidities or advanced age (470 years) treated with an CRT
consisting of two cycles cisplatin or carboplatin plus vinorelbine and a conventionally
fractionated radiotherapy up to 63Gy.
Results: Median survival of all patients was 13 months (10.6–15.4 months, 95% confidence
interval). Univariate analyses showed significantly poorer survival (12 months vs. 15
months) in patients with LVEFo50% compared with LVEFX50% (P ¼ 0.022, in log-rank
test). All other variables did not exhibit any significant correlation to survival. Multivariate
analyses revealed significantly inferior survival in patients suffering from cardiac or
pulmonary dysfunction (P ¼ 0.039, hazard ratio [HR]: 2.18; 95% CI of HR [1.04–4.59]).
Elderly patients (470 years) had a higher prevalence of hematotoxicity of higher degree
than younger patients (p70 years), but without significant impact on the feasibility of both
treatment modalities.Elsevier Ltd. All rights reserved.
4949000; fax: +49 381 4949002.
.uni-rostock.de (R. Fietkau).
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with a reduced survival in elderly or poor-risk patients with inoperable NSCLC after CRT.
& 2007 Elsevier Ltd. All rights reserved.Chemotherapy
Vinorelbine 
12.5 mg/m2 
10 min
Carboplatin 
AUC1 
or 
Cisplatin 
20 mg/ m2 
30 min
Radiotherapy
Single dose: 1.8 Gy (90% isodose), conventionally fractionated 
Total dose, target volume 1: 45.0-50.4 Gy (90% isodose) 
Total dose, target volume 2: 63.0 Gy (90% isodose)
Figure 1 Treatment protocol. Single dose: 1.8Gy (90%
isodose), conventionally fractionated. Total dose, target vo-
lume 1: 45.0–50.4Gy (90% isodose). Total dose, target volume
2: 63.0Gy (90% isodose).
Table 1 Inclusion criteria.
Poor general health (WHO-PS 2; WHO-PS 3 at patient’s
request)Introduction
Intensification of treatment through concurrent chemora-
diotherapy (CRT) has improved the survival of patients with
inoperable non-small cell lung cancer (NSCLC) without
distant metastases. This was unequivocally demonstrated
in four randomized clinical trials.1–4 These findings are also
reflected in the treatment recommendations of medical
societies.5 However, patients with advanced age, various
concomitant diseases or a low Karnofsky performance status
were excluded from many of these studies while in others
they represented only a small minority or were not included
because they were considered to be incapable of tolerating
cisplatin. Consequently, the mean age of patients in the
cited trials and other lung cancer trials is between 54 and 63
years.6
Only few authors have investigated the feasibility of
intensive treatment, i.e., concurrent CRT, in elderly and
poor-risk patients.7–10 These investigators have found that
individual combination chemotherapy with a platinum salt
and a new generation cytostatic agent resulted in a good
side effects profile. Still, overall survival in these patients
was lower than the rates achieved in other randomized
trials: median survival 10–13 months vs. 16–17 months
(see Fietkau11 for overview). The obvious questions, how-
ever, which comorbidities or general risk profiles do impact
on the survival of patients with inoperable NSCLC and which
prognostic criteria such as general state of health, age and
pretreatment weight loss predict response to treatment
and/or survival have not been addressed.
We therefore conducted a retrospective analysis of all 66
NSCLC patients with at least one type of organ dysfunction
or old age, who had received platinum-based concurrent
CRT with carboplatin or cisplatin plus vinorelbine to
determine how these objective patient- and tumor-related
factors would correlate with survival and toxicity.OR: Significant pretreatment weight loss: 5% three
months prior or 10% six months prior
OR: Compensated renal failure (creatinine clearance
30–60ml/min)
OR: Prior cardiac disease that inhibits a volume load of
more than 2 l (confirmed by a cardiologist), e.g., LVEF
o50%, atrial fibrillation, prior myocardial infarction, CHD
confirmed by coronary angiography, left or right
ventricular dilatation confirmed by echocardiography or
grade 41 heart valve defect
OR: Pulmonary dysfunction ( FEV1: o60%, 430%, or VC:
o60%,430%, DLCOo60%,430% of age-matched normal
values)
OR: Age 71–78 years
CHD: coronary heart disease; FEV1: forced expiratory volume
in 1 s; LVEF: left ventricular ejection fraction; DLCO: lung
transfer factor for diffusion impairment; VC: vital capacity;
WHO-PS: World Health Organization performance status.Patients and methods
Patient selection, classification of morbidity,
classification of acute toxicity and causes of death
The population contains all patients, who received con-
current CRT with vinorelbine and carboplatin or cisplatin
according to the scheme outlined in Figure 18,10 at the
Department of Radiotherapy at the University of Rostock,
Germany in the period from November 1998 to June 2005,
had stage I to IIIB (UICC classification) NSCLC that was
clinically inoperable but without evidence of distant
metastases. Results of the feasibility study were published
in 2003.8 All patients except for two had at least one of the
risk factors listed in Table 1. Patients treated within other
studies (e.g. Chartwell protocol; a phase II study withcisplatin/CPT—11) were excluded to have a homogenous
treatment of the patients.
All other patients (p70 years), in WHO PS 0 and 1,
medically fit for receiving cisplatin by cardiac and renal
function were treated with a different schedule and
excluded from this analyses due to the different inclusion
criteria, the rareness of risk factors and the potentially
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All cases investigated in this study had been rejected by
thoracic surgeons or aesthesiologists as inoperable.
The minimum requirements for lung function, kidney
function, WHO performance status and age included:
creatinine clearance430ml/min, forced expiratory volume
in 1 s (FEV1) 430%, VC 430%, DLCO (lung transfer factor,
regarding gas diffusion capacity) 430% of age-matched
normal value, WHO-PS X4; age o78 years and the usual
laboratory parameters. Patients who did not meet these
requirements were excluded from any CRT.
All patients were assessed by thoracic and abdominal
computed tomography and/or abdominal ultrasound and by
bone scintigraphy prior to treatment. Spirometry was
performed in 56/66 (85%) of cases, measurement of baseline
diffusion capacity in 51/66 (77%), and echocardiography in
54/66 (81%).
Left ventricular ejection fraction (LVEF) was the only
parameter of cardiac function used for the analysis. The
following parameters of pulmonary function were assessed:
vital capacity (VC), FEV1, and diffusing capacity represented
by the lung transfer factor (DLCO) using bodypletysmogra-
phy (Jaeger-Viasys, Hoechberg, Germany). These variables
were measured as values relative to the age-matched
normal values for the respective age group, and they were
weighted as a correlate of pulmonary function. Cardiac/
pulmonary dysfunction was defined using the following
threshold values: LVEF o50% and FEV1 o60%, VC o60%
or DLCO o60%. Reduced kidney function was defined as
creatinine clearance of less than 60ml/min.
Additional retrospective data on comorbidities were also
gathered from available referral letters and medical
reports. Comorbidities of interest were diabetes, psychiatric
or neurological disorders, and prior incidences of cancer.
The patient records were also searched for information
regarding alcohol or nicotine abuse. When such information
was found, the patient was classified as having a past or
present history of alcohol use, when consumption was
described as ‘‘daily’’ or ‘‘regular’’ or ‘‘occasional’’ with
more than one drink. Smoking abuse was defined in pack
years, if any present or former use was mentioned.
If no such information was found in the records, the
patient’s smoking/alcohol abuse status was defined as
‘‘not specified’’.
Data on the acute toxicity were collected retrospectively
and classified according to CTC-criteria.
The cause of death was ascertained in 49 of 61 (80%)
patients who had died by 6/2006 by locating the data in the
tumor register or by asking the last attending physician or
family doctor by phone. The causes of death could be
classified in the following broad etiological categories only:
intrathoracic tumor with or without pneumonia or heart
failure; metastasis-related, non-tumor-related.Concurrent chemoradiotherapy
Radiotherapy consisted of conventionally fractionated
radiotherapy of the primary tumor and suspicious lymph
nodes (41 cm) at a dose of up to 63Gy (90% isodose
envelope equals ca. 66Gy reference point dose) and
elective irradiation of mediastinal nodes ipsi—and contral-ateral with up to 45Gy/50.4Gy. In patients with upper
lobe tumors, the supraclavicular fossa was electively
irradiated with up to 45Gy, or with up to 50.4Gy in some
cases (48Gy/54Gy reference point dose). CT planning was
performed prior to treatment and was repeated after
delivery of 20Gy in cases of atelectasis or large tumors
and after 45Gy routinely. Three and four-field technique
using a 15MV linac was performed in each case. The mean
dose in both lungs was no more than 20Gy, and the
maximum dose to the spinal cord was 44Gy.
Chemotherapy consisted of two cycles of either carbo-
platin AUC 1 (up to the year 2000: 70mg/m2) or cisplatin
20mg/m2 on days 1–5 plus 12.5mg/m2 vinorelbine on days
1, 8, 15 in 28-day cycles. Dose modification was accom-
plished by shifting the time of application (vinorelbine: by
a few days, maximum: 7 days; cisplatin/carboplatin: by a
whole week). Up to the year 2001, the choice between
carboplatin and cisplatin was based on cardiac and renal
function reserve parameters; all later patients received
carboplatin/vinorelbine, due to the survival data of patients
with stage III NSCLC (unpublished data, with a trend of
better survival with vinorelbine/carbplatin of 21 months vs.
15 months for vinorelbine/cisplatin). To be eligible to
receive the chemotherapy drugs, the patients had to have
adequate bone marrow function, which was defined as a
peripheral leukocyte count of 43000ml1 and a peripheral
platelet count of 4100,000 ml1.
In order to compare the intensity and feasibility of
chemotherapy and radiotherapy in the different patient
subgroups, values were calculated using 90% of the
prescribed radiation dose (57Gy) and 50% of the prescribed
cisplatin/carboplatin dose (equals one cycle) plus 60% of the
prescribed vinorelbine dose (four vinorelbine infusions) as
threshold values.
Statistical analysis
The variables ‘‘organ dysfunction’’ and ‘‘age’’ were ana-
lyzed for the subgroups delineated by the threshold values
specified above. Survival was a continuous variable defined
as the interval, in months, between the time of diagnosis
and the date of death. Survival curves were calculated
according to the method of Kaplan–Meier. Log-rank tests
were used to compare the curves and test for differences in
effects of the individual category variables. Variables that
tended to have a one-dimensional effect on survival (Po0.2)
were analyzed using a multivariate model. Hazard ratios and
the 95% confidence interval (CI) were also calculated. The w2
test was used to test for differences in the frequency of
individual variables between groups.
Results
Demographics and morbidity
The median age of the population was 68 years (range
39–77). Because of the nature of the primary disease and
comorbidities, the majority of the patients (39/66 ¼ 60%)
were in a poor state of health (WHO performance status
2–3), and many had a history of nicotine/alcohol abuse.
Nearly all of the patients had a past or present history of
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had a past or present history of regular alcohol consumption
(not specified: 10). Significant pretreatment weight loss
occurred in 22/66 (33%) of the patients. The predominant
types of tumors in the population were locally advanced
tumors with mediastinal lymph node involvement, especially
stage IIIb tumors (46/66 ¼ 70% of patients). Further patient-
related information and data on tumor stage distribution
and histological classification are presented in Table 2.
The most common functional organ disorders and con-
comitant diseases were: pulmonary dysfunction: 25/51 (49%;
missing data: 15), myocardial dysfunction (LVEFo50%): 17/54
(31%, missing data: 12), combined cardiac/pulmonary dys-
function 36/50 (72%, missing data: 16), coronary artery
disease with a history of prior infarction or relevant coronary
artery stenosis: 17/66 (26%), diabetes mellitus: 13/66 (20%),
mild renal insufficiency (creatinine clearance: 30–60ml/min):Table 2 Patient characteristics.
Number of patients 66
Age (years)
Median; range 68; 39–77
Sex
Male 56 ¼ 85%
Female 10 ¼ 15%
WHO performance status
0 and 1 27 ¼ 40%
2 and 3 39 ¼ 60%
Marital status
Married 49 (74%)
Unmarried 9 (14%)
Not specified 8 (12%)
Nicotine abuse
Past and present 58 (88%)
Negative 3 (4%)
Not specified 5 (8%)
Alcohol abuse
Negative 29 (44%)
Past and present 27 (41%)
Not specified 10 (15%)
Tumor stage
I and II 8 ¼ 12%
IIIa 12 ¼ 18%
IIIb 46 ¼ 70%
Tumor extent
T1and T2 20 ¼ 30%
T3 16 ¼ 24%
T4 30 ¼ 46%
N0 and N1 19 ¼ 29%
N2 25 ¼ 38%
N3 22 ¼ 33%
Histology
Squamous cell carcinoma 41 ¼ 62%
Adenocarcinoma 17 ¼ 26%
Other non-small-cell carcinoma 8 ¼ 12%13/66 (20%), and psychiatric or neurological disorders: 11/60
(18%, missing data: 6). In nine cases, NSCLC was the second or
third malignant lesion (prior tumors: prostatic carcinoma:
n ¼ 3, ear–nose–throat tumor: n ¼ 2, bladder cancer: n ¼ 2,
malignant melanoma: n ¼ 1, germ cell tumor: n ¼ 1, renal
cell carcinoma: n ¼ 1).
The w2 test was used to test for differences between 4
70-year-olds andp70-year-olds. The groups did not differ in
terms of the frequency of kidney disease (7/24 vs. 6/42;
P ¼ 0.144), pulmonary dysfunction (9/20 vs. 16/31;
P ¼ 0.645), myocardial dysfunction (5/18 vs. 12/36;
P ¼ 0.679), diabetes (6/24 vs. 7/40; P ¼ 0.470), or history
of cancer (4/22 vs. 5/38; P ¼ 0.599), psychiatric or
neurological disorders (3/22 vs. 8/38; P ¼ 0.474), significant
pretreatment weight loss (7/24 vs. 15/42; P ¼ 0.587), and
poor general health (WHO performance status 2/3) (14/24
vs. 25/42; P ¼ 0.925).Age, morbidity and treatment toxicity
The side effects of treatment were moderate and mostly
myelotoxic in nature. Grade 3 or 4 thrombocytopenia
occurred in 18/66 (27%) patients, and grade 3 or 4
leukocytopenia in 28/66 (42%). Local toxicity was manage-
able; 5% of patients developed severe and very severe
esophagitis (grade 3: 2, grade 4: 1), and two (3%) developed
clinically relevant pneumonia (grade 3). One patient died
during treatment without an unequivocally determinable
cause of death. A post mortem examination was not
declined. The 30-day mortality after completion of treat-
ment was 4/66 (6%). Since there were only sporadic reports
of late toxicities, this data was not included in the analysis.
All 66 patients received at least one dose of vinorelbine
and one cycle of cisplatin or carboplatin. Sixty-two patients
received at least 90% of the prescribed radiotherapy dose,
and 41 (62%) of the patients received at least one
carboplatin or cisplatin cycle (50% dose level) and four
vinorelbine doses (60% dose level).
Advanced age (470) did not impair the feasibility of
radiation therapy. All 24 patients over 70 received more
than 90% of the prescribed radiotherapy dose compared to
38/42 (90%) of the younger patients (P ¼ 0.079). Only 12/24
(50%) of patients over 70 received at least four doses of
vinorelbine and one cycle of cisplatin or carboplatin
compared to 29/42 (69%) of the younger patients
(P ¼ 0.125). In addition, there were significantly higher
rates of grade 3–4 thrombocytopenia (11/24 vs. 7/42;
P ¼ 0.010) and grade 3–4 leukocytopenia (14/24 vs. 14/24;
P ¼ 0.048) in the patients over 70 than in the younger
patients.
Patients with cardiac/pulmonary dysfunction (LVEFo50%,
FEV1o60% or VCo60% or DLCOo60%) received 90% of the
prescribed radiotherapy dose just as frequently (33/36 vs.
13/14; P ¼ 0.889) and received 60% of the vinorelbine
dose+50% of the carboplatin or cisplatin dose (21/36 vs.
8/14; P ¼ 0.939) just as frequently as patients without
cardiac/pulmonary dysfunction. The stage of the disease
(stage 1–2 vs. stage 3) also did not affect the frequency
of receiving an adequate dose intensity of radiotherapy
(8/8 vs. 53/58; P ¼ 0.388) or chemotherapy (5/8 vs. 36/58;
P ¼ 0.388).
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radiotherapy (26/27 vs. 25/29 patients received an ade-
quate dose; P ¼ 0.186), but did decrease the patient’s
chances of receiving an adequate chemotherapy dose
(abstinent: 22/29 vs. positive history of alcohol: 12/27;
P ¼ 0.016). Patients with a past or present history of alcohol
consumption showed a tendency to develop leukocytopenia
more often (15/27 vs.10/29; P ¼ 0.113), and they devel-
oped grade 3–4 thrombocytopenia significantly more often
(13/27 vs. 3/29; P ¼ 0.002).Survival
Sixty-one (92%) of the 66 patients had died by the data cut-
off date (1 October 2006). The cause of death was
determined in 49 cases: intrathoracic tumor with or without
pneumonia or heart failure (cardiac dysfunction): 32/61
(53%), death due to metastases to the brain (6/61 ¼ 10%) or
liver (2/61 ¼ 3%); in 3/61 (5%) of these patients, death was
attributed to both the metastatic and thoracic tumor
situation. Six of the 61 patients (10%) died of causes
unrelated to cancer. Four of them (7%) died of heart failure
and one of cerebral ischemia; the sixth patient committed
suicide.Table 3 Univariate analysis of potential prognostic factors for s
inoperable bronchial carcinomas.
Parameter Median
surviva
Sex
Male: N ¼ 56 13 mos
Female: N ¼ 10 07 mos
Age
p70 years: N ¼ 42 15 mos
470 years: N ¼ 24 12 mos
Marital status
Married: N ¼ 49 14 mos
Unmarried: N ¼ 9 23 mos
WHO performance status
0/1: N ¼ 27 15 mos
2/3: N ¼ 39 12 mos
Pretreatment weight loss
Positive: N ¼ 22 13 mos
Negative: N ¼ 44 13 mos
Histology
Squamous cell carcinoma: N ¼ 41 14 mos
Adenocarcinoma: N ¼ 17 12 mos
Nicotine abuse
Negative: N ¼ 3 Not ap
Past and present: N ¼ 58 13 mos
Alcohol abuse
Negative: N ¼ 29 15 mos
Past and present: N ¼ 27 12 mosCumulative median survival for the overall population was
13.0 months (95% CI: 10.6 months; 15.4 months). The 1, 2, 3
and 5-year survival rates were 53% (S.D.76.1%), 21.2%
(75.0%), 11.9% (74.0%) and 6.8% (73.2%), respectively.
Univariate and multivariate analyses were performed to
determine the effect of various tumor and patient-related
variables on survival. The univariate analysis showed a
significant impact of pretreatment cardiac dysfunction,
which was defined as a decreased left ventricular ejection
fraction, on survival (P ¼ 0.02 by log-rank test; HR ¼ 1.97,
95% CI of HR: 1.07–3.63).
Gender, age, marital status, WHO performance status,
pretreatment weight loss, tumor stage and histological
classification, and other concomitant diseases did not
exhibit any significant correlation. Table 3 shows the data
for median survival (with 95% confidence interval), 1-year
survival, 2-year survival (7standard deviation) and the
corresponding P-values, as calculated using the log-rank
test.
The multivariate analysis was used to assess data that
the univariate analysis identified as showing statistical
trends (Po0.20). Because of the low number of patients
in the individual groups, cardiac dysfunction and pulmonary
dysfunction were combined as a single group, as were
the UICC tumor stages. In this analysis, the presence of
cardiac/pulmonary dysfunction vs. the absence of cardiac/urvival following concurrent chemoradiation for treatment of
l
One-year
survival
Two-year
survival
P-value
(11;15) 53.6%706.7% 19.6%705.3% 0.559
(00;30) 50.0%715.8% 30.0%714.5%
(10;20) 57.1%707.6% 23.8%706.6% 0.424
(08;16) 45.8%710.2% 16.7%707.6%
(11;17) 55.1%707.1% 22.4%706.0% 0.821
(4;42) 55.6%716.6% 22.2%713.9%
(12;18) 59.3%709.5% 11.1%706.0% 0.687
(09;15) 48.7%708.0% 38.5%707.8%
(07;19) 54.5%710.6% 36.4%710.3% 0.218
(10;16) 52.3%707.5% 13.6%705.2%
(11;17) 56.1%707.8% 24.4%706.7% 0.570
(09;15) 41.2%711.9% 11.8%707.8%
plicable
(11;15) 53.4%706.5% 19.0%705.1%
(12;18) 58.6%709.1% 31.0%708.6% 0.050
(05;19) 48.1%709.6% 14.8%706.8%
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Parameter Median
survival
One-year
survival
Two-year
survival
P-value
Tumor stage
I and II: N ¼ 8 19 mos (00;40) 75.0%715.3% 50.0%717.7% 0.112
III: N ¼ 58 12 mos (09;15) 50.0%706.6% 17.2%705.0%
IIIa: N ¼ 12 13 mos (03;22) 58.3%714.2% 0% 0.648
IIIb: N ¼ 46 12 mos (10;15) 47.8%707.4% 21.7%706.1%
T1, T2: N ¼ 20 19 mos (06;32) 75.0%709.7% 25.0%709.7% 0.239
T3, T4: N ¼ 46 12 mos (09;14) 43.5%707.3% 19.6%705.8%
N0, N1, N2: N ¼ 44 14 mos (09;19) 56.8%707.5% 25.0%706.5% 0.072
N3: N ¼ 22 12 mos (09;15) 45.4%710.6% 13.6%707.3%
Chemotherapy
Carboplatin/vinorelbine: N ¼ 59 14 mos (10;16) 59.3%706.4% 23.7%705.5% 0.386
Cisplatin/vinorelbine: N ¼ 7 17 mos (04;30) 57.1%718.7% 28.6%717.1%
Pulmonary dysfunction
(FEV1o60% or VCo60% or DLCOo60%)
Positive: N ¼ 25 9 mos (06;12) 28.0%709.0% 16.0%707.3% 0.121
Negative: N ¼ 26 15 mos (12;18) 69.2%709.1% 15.4%707.1%
Cardiac dysfunction
(LVEFo50%)
Positive: N ¼ 17 12 mos (08;16) 35.3.6%711.6% 05.9%705.7% 0.022
Negative: N ¼ 37 15 mos (09;20) 59.5%708.1% 24.3%707.1%
Cardiac or pulmonary dysfunction
(LVEFo50% or FEV1o60% or VCo60% or DLCOo60%)
Positive: N ¼ 36 11 mos (08;14) 36.1%78.0% 11.1%705.2% 0.074
Negative: N ¼ 14 21 mos (15;26) 71.4%712.1% 21.4%711.0%
Renal dysfunction
Positive: N ¼ 13 16 mos (01;31) 53.8%713.8% 30.8%712.8% 0.863
Negative: N ¼ 53 13 mos (11;15) 52.8%706.9% 18.9%705.4%
Diabetes
Positive: N ¼ 13 16 mos (09;16) 69.2%712.8% 15.4%710.0% 0.943
Negative: N ¼ 51 12 mos (12;20) 49.0%707.0% 21.6%705.8%
Prior malignant disease
Negative: N ¼ 9 13 mos (10;16) 51.0%707.0% 19.6%705.6% 0.452
Positive: N ¼ 51 23 mos (0;46) 77.8%713.9% 33.3%715.7%
Psychiatric or neurological disorders
Negative: N ¼ 49 14 mos (11;17) 51.0%707.1% 22.4%706.0% 0.900
Positive: N ¼ 11 13 mos (11;15) 63.6%714.5% 18.2%711.6%
FEV1: forced expiratory volume in 1 s; mos: months; DLCO: lung transfer factor; VC: vital capacity.
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parameter for survival (Table 4). Patients with cardiac/
pulmonary dysfunction had significantly poorer survival
rates than those without cardiac/pulmonary dysfunction
(adjusted HR ¼ 2.185, P ¼ 0.039, 95% CI for HR:
1.039–4.594) (Figure 2).Discussion
This analysis suggests that in this population cardiac or
pulmonary dysfunction may have an impact on the prognosis
of patients with inoperable NSCLC. Until today, objectivecardiac/pulmonary dysfunction has rarely been regarded in
clinical trials or in treatment guidelines. Patients with
cardiac/pulmonary dysfunction are generally excluded from
clinical trials in order to ensure proper interpretation of
results or to protect patients with such organ dysfunctions
from potentially hazardous side effects.
In routine clinical practice, patients are most often
excluded from concurrent CRT for three reasons: advanced
age, poor health status and comorbidities, which are
weighted differently by different clinicians mainly based
on individual experience. Our present work might aid in
the assessment of these frequent yet critical patients.
Elderly individuals and those with concomitant diseases are
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Table 4 Multivariate Cox regression analysis of potential prognostic factors following concurrent chemoradiation for
treatment of inoperable bronchial carcinomas.
Parameter P-value Adjusted hazard
ratio
95% Confidence
interval
Alcohol consumption
Past/present vs. abstinent 0.068 1.812 0.957–3.431
Tumor stage
UICC III vs. UICC I and II 0.148 2.219 0.755–6.525
Cardiac/pulmonary dysfunction
FEV1o60% or VCo60% or DLCOo60% or LVEF o50%
vs. FEV1X60% and VCX60% and LVEFX50%

0.039 2.185 1.039–4.594
FEV1: forced expiratory volume in 1 s; mos: months; DLCO: lung transfer factor; UICC: International Union Against Cancer; VC: vital
capacity.
Reference.
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Figure 2 Overall survival curves (%) according to cardiac/
pulmonary dysfunction. Solid line: FEV1X60% and VCX60% and
DLCOX60% and LVEFX50%. Dotted line: FEV1o60% or VCo60%
or DLCOo60% or LVEFo50%.
S. Semrau et al.216generally classified as those with a poor performance. The
percentage of 470-year-olds in our study population was
36% and the median age was 68 years. So compared to other
clinical trials investigating the efficacy of concurrent CRT for
optimization of treatment for patients with inoperable
NSCLC1,3 it was 14 to 4 years higher. The French NPC 95-01
trial3 excluded all patients over 70 years. In addition, the
patients in previous trials tended to be in a good to very
good state of general health. Although the Japanese1 and
Czech studies4 did include some patients with WHO
performance status 2, the percentage of these patients
was marginal (5–10%). Firat et al.12 found in their systematic
analysis that many investigators assume that old age alone
implies an inability to tolerate chemoradiation and that,
consequently, these patients received concurrent CRT less
often than other cancer patients, even through age is not an
independent factor for survival.
Age is indisputably the most comparable parameter in all
studies. Our retrospective analysis shows no indication that
the 470-year-olds in the population had a poorer survival
because of advanced age alone. These results differ from
those of the ‘‘recursive partitioning analysis’’ performed by
the Radiation Therapy Oncology Group (RTOG) in 1999, aretrospective analysis of data from clinical trials performed
from 1983 to 1994. Radiation therapy was the predominant
form of treatment in these patients with locally advanced
NSCLC.13 Most of the 470-years-olds in the RTOG analysis
had a poorer prognosis than the younger patients. Other
unfavorable factors were: large-cell tissue components,
malignant pleural effusion, and a low Karnofsky perfor-
mance status (o90%).13 At the same time, we infer that the
recruited patients were in good general condition. In a later
retrospective analysis in which the RTOG excluded some of
its earlier treatment escalation studies (RTOG 88-4, RTOG
83-21), age over 70 did not appear as a negative factor.14
Movsas et al.14 also analyzed the effect of old age on survival
of NSCLC patients who received intensified treatment. Their
analysis shows that 71-year-old patients also reached the
longest survival time after concurrent CRT as well as after
standard radiotherapy (14.1 vs. 13.1 months). However, only
a very small number of patients received concurrent CRT in
this study. Considering the questionable information value of
these studies, more recent phase II trials and case studies
provide more valid data on this patient subgroup. In the
RTOG 94-10 study, for example, a subgroup analysis showed
that ‘‘fit elderly patients’’ had even better survival rates
than younger patients.15 Schild et al.16 showed that patients
of 70 years and older achieve comparable median survival
rates after concurrent radiation and chemotherapy with
etoposide and cisplatin vs. hyperfractionated radiation
therapy. This is in agreement with Atagi et al.17 who found
that concurrent radiation and daily low-dose carboplatin can
be successfully applied in 475-year-olds, with the pre-
dominant dose-limiting toxicity being hematotoxicity.
Although the 470-year-olds in our study population were
not healthier than the patients under 70, our results still
support this change in mindset towards age. When treating
elderly patients, one must consider that there are more
limitations on dose adjustment of cytostatic drugs in these
patients, and that they have higher rates of thrombo- and
leukocytopenia which, in most cases, did not result in a
decreased dose of chemotherapy for the selected drug
combinations and doses. However, this also implies that
there are limitations and hazards during and immediately
after concurrent CRT.
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cially those involving organ function or functional deficits
due to habitual intoxication, had a greater impact on
survival than age.
In previous studies, comorbidities have been mainly
analyzed using comorbidity scores. The advantage of scoring
systems is that they can paint an overall picture of the
patient’s health status by rating target parameters items
using graduated scales. Investigators using the Cumulative
Illness Rating Scale for Geriatrics (CIRSG) determined that
concurrent CRT correlated with poorer survival more than
radiotherapy alone in patients with high CIRSG scores.12
Other scoring systems, such as the Charlson Index, did not
show any reproducible correlation.18 These findings are
ambivalent, especially since the scoring systems cannot
be tested prospectively using stratification instruments.
The use of an overall score is problematic when the side
effects of treatment are less global in nature, but are more
organ-related.
A number of parameters commonly used for scoring of
concomitant diseases did not exhibit any effect on survival
in our retrospective analysis. We did not find any evidence
that diabetes, controlled prior malignant diseases or kidney
failure had a negative effect on survival provided that
potential complications were considered when selecting
carboplatin or cisplatin for chemotherapy.
On the other hand, pretreatment cardiac and pulmonary
dysfunction had an independent significant effect. Never-
theless one must be aware of the fact, that the small
number of patients and the retrospective character of the
analysis are limitations of our study. Therefore, the results
of our study should be considered as an advice to investigate
these parameters in further prospective trials. The main
objective of our study was to investigate easily available,
objective and reproducible pathophysiological parameters,
describing the broad spectrum of comorbidies. In contrast to
previous results12 patients with weight loss and low
performance status or stage III showed only a tendency to
have a reduced survival rate but the missing significance
may also be an effect of the small patient number.
The reason why patients with pulmonary or cardiac risk
factors have a poorer prognosis remains an open question.
Three hypotheses have been proposed: Patients with myocardial dysfunction have, a priori, a
poor prognosis. Mortality rates of 16% within a 6-month
period in patients with a decreased ejection fraction
have been reported.19 The same is true for COPD,
although mortality rates may be lower.20 Myocardial dysfunction and pulmonary dysfunction impair
the feasibility of CRT in that they necessitate a reduction
of dose intensity. Our data do not support this hypothesis. In the long term, intensified treatment (concurrent
radiochemotherapy) could lead to disproportionate ex-
acerbations of existing myocardial and pulmonary dis-
orders causing patients to die sooner than from the
natural course of the disease. A definitive answer to
these questions requires further analysis.An association between radiotherapy and myocardial fibro-
sis, valvular lesions and pericarditis has been reported.21,22Little data is available concerning their temporal relation-
ship. Results of epidemiological long-term toxicity studies of
cardiac mortality following radiation therapy have been
published for Hodgkin’s disease,23 breast cancer,24 and
childhood cancer25; evidence of significant cardiac mortality
and mortality following radiotherapy for breast cancer was
found. However, this situation is not comparable to our
present study where most of the NSCLC patients had normal
cardiac function at the beginning of treatment, the
irradiated ventricular volume was small, and the total
radiation doses were lower. In patients with breast cancer,
on the other hand, anthracyclines are frequently used.
Patients with esophageal cancer have a comparable prog-
nosis and a similar cardiac status. Ishikura et al.26 observed
lethal myocardial infarction in 3% of their esophageal cancer
patients, 2% of whom had clinically manifest pneumonia or
heart failure, respectively, and 8% of whom had sympto-
matic pericarditis. Short- and medium-term cardiac
side effects can be characterized according to the CTC
and LENT classifications, which attract little interest up to
now considering that most of the patients have tumor
recurrences.
Apart from cardiac toxicity, little is known about
pulmonary compensation potentials following radiotherapy,
e.g., secondary increase in right ventricular afterload due to
impairment of the pulmonary flow bed, tumor-related
necrosis, interstitial fibrosis, or hypoxygenation due to
extension of the diffusion pathway in conjunction with
frequency stress. This information is speculative. Still, the
expectation of long-term survival in the patients is
associated with a risk of cardiopulmonary morbidity and
impaired quality of life. Consequently, further research on
this subject must be performed.
The next question is, ‘‘What are the consequences for
treatment?’’ In NSCLC patients with myocardial or pulmon-
ary dysfunction, median survival following concurrent CRT is
at least as good as that achieved with radiotherapy alone
(see review by Fietkau11). One can therefore assume that
concurrent CRT does, at least, not cause additional harm to
patients. There is still the question of whether concurrent
CRTcould be improved by reducing the irradiation volume or
by changing the irradiation technique (to protect the
irradiated heart volume). Furthermore, age-adjusted selec-
tion and administration of the chemotherapy drugs is
essential. Inversely, we observed that patients with good
cardiopulmonary function had a prognosis that was virtually
the same as that of patients with surgically treated stage III
NSCLC.Conclusions
Elderly patients and patients with multiple comorbidities
tolerate concurrent CRT, and age was not associated with
increased treatment-related morbidity or a poorer prog-
nosis. However, the incidence of significant hematotoxicity
has higher in these patients.
Cardiac/pulmonary dysfunction may be an independent
prognostic parameter in patients with concomitant diseases.
Considering the frequency of occurrence of these impair-
ments, further investigation in epidemiological and morpho-
logical cross-sectional and longitudinal studies is required.
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